IonStar could upend industry standards, and quicken medical diagnosis and drug development
A new protein analysis tool developed at the University at Buffalo could vastly increase the speed and precision with which disease and drug effects are analyzed.
The groundbreaking tool, called IonStar, is the first to provide near-perfect accuracy when quantifying and comparing the abundance of proteins in the bodies of people who are healthy and ill.
Compared to industry standard MaxQuant, IonStar improved the measurement consistency of proteins in low abundance and lowered the amount of missing data in results from 17 percent to 0.1 percent, a level that has never been achieved with large samples.
The new tool could increase the quality and accuracy of medical diagnosis and quicken the pace of pharmaceutical development.
“IonStar will totally change the face of clinical and pharmaceutical research and industry, where large investigations are often critical,” says Jun Qu, PhD, lead investigator and professor in the UB School of Pharmacy and Pharmaceutical Sciences.
The research was published yesterday in the Proceedings of the National Academy of Sciences (PNAS).
Playing spot the difference
The abundance of proteins in the body that correspond with disease or pharmaceutical reactions can provide researchers with vital clues for accurately diagnosing a condition, and for developing potential therapies and evaluating drug effects.
Protein analysis tools are used to quantify and compare the abundance of proteins in groups of healthy individuals with those who are ill or treated with a drug. Changes in protein abundances, when analyzed together, often reveal novel biomarkers.
The challenge for researchers is that current tools are not efficient at analyzing large numbers of samples. One type of method, the labeling-method, uses chemical tags to label proteins. The issue: The software can only analyze up to 10 samples at a time, making it difficult for researchers to conduct typical pharmaceutical and clinical studies, says Qu.
The alternative, the label-free method, can analyze a large number of samples at once at the expense of accuracy and precision, causing researchers to waste time and resources validating falsely identified biomarkers.
IonStar increases accuracy and precision and lowers missing data by improving on sample preparation methods, alignment and feature detection designs for mass spectrometry analysis.
“For example, in clinical trials, comparing a handful of patients gets you nowhere,” says Qu. “If you can analyze a large number of patients with high-quality data, you can discover and track biomarkers much more accurately and reliably. The same is true for pharmaceutical investigations.”
Proving the concept in traumatic brain injury
Researchers used IonStar to quantify proteins in rats with traumatic brain injury, a debilitating condition that accounts for 2.2 million emergency room visits annually in the United States.
Using 100 tissue samples, IonStar identified 7,000 proteins, including 1,000 that differed in abundance, without missing data.
IonStar also measured low-abundance proteins with higher accuracy and precision than other prevalent analysis tools. This capability is critical, says Qu, because proteins that appear in smaller amounts play a more influential role in the body.
“If higher-level proteins are soldiers, then lower-level proteins are the commanders. They are the regulators that tell the higher-level proteins what to do,” says Qu.
Qu has used IonStar and similar techniques to analyze protein variation in cancer, diabetes, cardiovascular disease, neurodegeneration and retina degeneration as well.
Future work on IonStar will focus on expanding the number of samples the tool can analyze.
The Latest on: Drug development
via Google News
The Latest on: Drug development
- Implantable Drug Delivery Devices Market - Technology, Trends, Development, Key Manufacturers Analysis and Forecast to 2025 on December 17, 2018 at 5:20 pm
Worldwide Implantable Drug Delivery Devices Market Analysis to 2025 is a specialized and in-depth study of the Implantable Drug Delivery Devices industry with a focus on the global market trend. […]
- Chronic Respiratory Disease Drug Development Pipeline Review 2018 Featuring AstraZeneca, GlaxoSmithKline and Galapagos - ResearchAndMarkets.com on December 17, 2018 at 12:55 pm
DUBLIN--(BUSINESS WIRE)--The "Chronic Respiratory Disease Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering. This report Chronic Respiratory ... […]
- Research opens door to development of drug or vaccine for late-onset Alzheimer's on December 17, 2018 at 9:11 am
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer's disease, opening the door to development of a drug that could be administered ... […]
- Global Infectious Disease Therapeutics Market 2019-2023 | Development of Novel Drugs to Boost Demand | Technavio on December 17, 2018 at 7:20 am
The global infectious disease therapeutics market is expected to post a CAGR of over 4% during the period 2019-2023, according to the latest market research report by Technavio. This press release fea... […]
- National Biofilms Innovation Centre award grant to Neem Biotech for novel anti-biofilm drug development on December 17, 2018 at 7:00 am
Neem Biotech, a company focused on developing novel solutions to address antimicrobial resistance, together with the Welsh Wound Innovation Centre and Sheffield Collaboratorium for Antimicrobial Resis... […]
- Transplant Complications Drug Development Pipeline Review 2018: Therapeutics Development, Assessment, Companies, Dormant & Discontinued Projects and Product Development ... on December 17, 2018 at 6:24 am
DUBLIN--(BUSINESS WIRE)--The "Transplant Complications Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering. Transplant Complications Drug Development Pip... […]
- Lilly, AC Immune to collaborate on Alzheimer’s drug development on December 17, 2018 at 12:41 am
Eli Lilly and Company (Lilly) and AC Immune have signed a license and collaboration agreement, potentially worth around CHF1.89bn ($1.9bn), for research and development of tau aggregation inhibitor sm... […]
- World's Top 20 AI Drug Development Companies on December 16, 2018 at 1:17 pm
As Margaretta Colangelo, Partner at Deep Knowledge Ventures, mentions in her recent article 'Although pharmaceutical companies spend over $172 billion on research and development annually, over 90% of ... […]
- FDA hails 2018 as bumper year for drug development successes on December 13, 2018 at 5:25 am
The FDA has hailed 2018 as a standout year for drug development and approvals, both in terms of the quantity and quality of activity. With the FDA approving 55 new molecular entities (NMEs) over the f... […]
via Bing News